Opzelura (ruxolitinib) cream is an FDA-approved prescription treatment for two skin conditions: atopic dermatitis (eczema) and nonsegmental vitiligo. It’s the first topical JAK inhibitor approved in the United States, offering a non-steroidal option for people whose skin hasn’t responded well to other treatments or who need an alternative to long-term steroid use.
The Two Conditions Opzelura Treats
Opzelura is approved for mild to moderate atopic dermatitis in patients aged 2 and older, and for nonsegmental vitiligo in patients aged 12 and older. These are its only two FDA-approved uses, though the same active ingredient exists in oral form for other conditions.
For eczema, it targets the itching, redness, and inflammation that define flare-ups. For vitiligo, it works to restore lost skin color in the white patches caused by the immune system attacking pigment-producing cells. The cream is applied differently depending on which condition you’re treating: up to 20% of your body surface area for eczema, or up to 10% for vitiligo. In both cases, you apply a thin layer twice daily.
How It Works
Both eczema and vitiligo involve an overactive immune response. In eczema, the immune system triggers excessive inflammation in the skin. In vitiligo, it destroys the cells responsible for producing melanin, the pigment that gives skin its color.
Opzelura works by blocking a specific signaling pathway (called JAK) that immune cells use to drive these processes. When you apply the cream, it dials down that overactive immune signaling right at the skin’s surface. For eczema, this calms the inflammation and itch cycle. For vitiligo, reducing immune activity in the affected area allows healthy pigment-producing cells to gradually regrow, and repigmentation slowly returns over weeks to months.
How Quickly It Works for Eczema
Itch relief can begin surprisingly fast. In clinical studies, some patients reported meaningful improvement in itch as early as day 2. By one week, 27.4% of patients had a clinically significant reduction in itch scores, compared to just 9% using a plain moisturizer cream. By week 8, that number climbed to 62.5%, versus 19.8% for the placebo group.
That early itch relief matters because the itch-scratch cycle is one of the most damaging aspects of eczema. Breaking it quickly can prevent the skin thickening and damage that come from chronic scratching.
What to Expect With Vitiligo
Repigmentation is a much slower process than itch relief. The cream promotes the gradual growth of new, healthy pigment-producing cells in affected areas, but visible results typically take months rather than weeks. Clinical trials measured outcomes at 24 and 52 weeks, and results continued to improve over the full year of treatment. If you’re using Opzelura for vitiligo, patience is essential. It’s not a quick fix, but it is the first FDA-approved topical treatment specifically for this condition.
Common Side Effects
Side effects differ somewhat depending on which condition you’re treating, largely because of differences in how much skin is covered and how long treatment lasts.
For eczema in adults and teens, the most common side effects in clinical trials were mild: nasopharyngitis (common cold symptoms) at 3%, along with bronchitis, ear infections, hives, diarrhea, and folliculitis each at about 1%. In children ages 2 to 11, upper respiratory infections were more common at 15%, with application site reactions at 5%.
For vitiligo, the side effect profile looks a bit different because the cream sits on the skin for longer treatment courses. The most frequently reported reactions were:
- Acne at the application site: 6%
- Itching at the application site: 5%
- Cold symptoms: 4%
- Headache: 4%
- Redness at the application site: 2%
Most of these are mild and localized. The application site reactions (acne, itching, redness) tend to be the most noticeable day-to-day issue.
Safety Considerations
Opzelura carries a boxed warning, the FDA’s most serious safety label. This warning is based on risks observed with oral JAK inhibitors taken systemically at much higher doses for conditions like rheumatoid arthritis. Those risks include serious infections, blood clots, cardiovascular events, and certain cancers. Whether these risks meaningfully apply to a topical cream used on limited skin areas at much lower systemic absorption is still a subject of ongoing evaluation, but the FDA requires the warning as a class-level precaution for all JAK inhibitors.
Because of this, the body surface area limits (20% for eczema, 10% for vitiligo) aren’t just guidelines. They’re there to minimize how much of the drug gets absorbed into the bloodstream. Opzelura is also not recommended for use in combination with other JAK inhibitors, biologics, or other potent immune-suppressing medications.
How It Compares to Steroids
For eczema, topical steroids have been the standard treatment for decades, but they come with well-known drawbacks: skin thinning, stretch marks, and rebound flares with long-term use. Opzelura doesn’t carry those steroid-specific risks, which makes it a useful option for sensitive areas like the face, neck, and skin folds where steroids are particularly problematic. It also doesn’t have the same time limits that dermatologists typically place on steroid use.
For vitiligo, there was no FDA-approved topical treatment before Opzelura. Dermatologists previously relied on off-label options like potent topical steroids and calcineurin inhibitors, along with phototherapy. Opzelura gave patients the first purpose-built, clinically tested topical option for restoring pigment.